The Top 5 Biosimilar Articles for the Week of January 4

Here are the top 5 biosimilar articles for the week of January 4, 2021.

Number 5: China’s National Medical Products Administration (NMPA) has approved Innovent Biologics’ adalimumab biosimilar (Sunlino) for new indications.

Number 4: Providers should feel confident using Mvasi, a bevacizumab biosimilar, for all indications of the reference product (Avastin), reviewers stated.

Number 3: Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.

Number 2: Alvotech has moved forward with expansion of its Reykjavik, Iceland, facilities to speed up development and put the company on its way to launching its first biosimilars.

Number 1: A study of uptake of the trastuzumab biosimilar ABP 980 (Kanjinti) in Europe found strong uptake patterns, according to an abstract presentation at the 2020 San Antonio Breast Cancer Symposium.

To read all of these articles and more, visit centerforbiosimilars.com.